{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-123809","form_type":"8-K","ticker":"VYGR","cik":"0001640266","company_name":"Voyager Therapeutics, Inc.","filed_at":"2023-12-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.906621+00:00","generated_at":"2026-06-07T17:08:16.935431+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Voyager selects lead candidate for SOD1-ALS gene therapy; IND filing expected mid-2025","bullets":["Lead candidate combines siRNA construct with IV-delivered TRACER capsid targeting SOD1-mutated ALS.","Non-human primate study showed 73% reduction of SOD1 in cervical spinal cord motor neurons after single IV dose.","Another preclinical candidate previously increased survival by median 152 days in G93A mouse model.","Additional candidate data to be presented at upcoming scientific conference."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-123809","json":"https://secwatch.observer/filing/0001104659-23-123809.json","markdown":"https://secwatch.observer/filing/0001104659-23-123809.md","text":"https://secwatch.observer/filing/0001104659-23-123809.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1640266/000110465923123809/0001104659-23-123809-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1640266/000110465923123809/tm2332263d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T17:08:16.935431+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}